MedTrace Logo

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2025-01-31

No results posted yet for this study

Summary

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Conditions

Interventions

BEHAVIORAL

Nutrition

Standardized advice on healthy diet practices.

BEHAVIORAL

Exercise

Standardized advice on exercise including strength training and resistance training exercises.

BEHAVIORAL

Smoking cessation

Advice to quit smoking, if applicable, and on available aids to quit smoking,

DRUG

Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.

DRUG

ACE inhibitor

Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.

Sponsors & Collaborators

  • Prostate Cancer Canada

    collaborator OTHER

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-21
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • Colombia
  • Israel
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03127631 on ClinicalTrials.gov